{"nctId":"NCT01328444","briefTitle":"An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A","startDateStruct":{"date":"2011-03-01"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":349,"armGroups":[{"label":"GSK 573719 + GW642444 125/25","type":"EXPERIMENTAL","interventionNames":["Drug: GSK573719 + GW642444 62.5/25","Drug: GSK 573719 125","Drug: GW642444 25","Drug: Plb"]},{"label":"GSK 573719 +GW642444 62.5/25","type":"EXPERIMENTAL","interventionNames":["Drug: GSK 573719 +GW642444 125/25","Drug: GSK 573719 62.5","Drug: GW642444 25","Drug: Plb"]},{"label":"GSK 573719 125","type":"EXPERIMENTAL","interventionNames":["Drug: GSK 573719 +GW642444 125/25","Drug: Plb"]},{"label":"GSK 573719 62.5","type":"EXPERIMENTAL","interventionNames":["Drug: GSK573719 + GW642444 62.5/25","Drug: GW642444 25","Drug: Plb"]},{"label":"GW 642444 25","type":"EXPERIMENTAL","interventionNames":["Drug: GSK 573719 +GW642444 125/25","Drug: GSK573719 + GW642444 62.5/25","Drug: Plb"]},{"label":"Plb","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: GSK 573719 +GW642444 125/25","Drug: GSK573719 + GW642444 62.5/25","Drug: GSK 573719 125","Drug: GSK 573719 62.5"]}],"interventions":[{"name":"GSK 573719 +GW642444 125/25","otherNames":["High Dose Dual"]},{"name":"GSK573719 + GW642444 62.5/25","otherNames":["Low Dose Dual"]},{"name":"GSK 573719 125","otherNames":["High Dose 719"]},{"name":"GSK 573719 62.5","otherNames":["Low Dose 719"]},{"name":"GW642444 25","otherNames":["LABA (444)"]},{"name":"Plb","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type of subject: Outpatient.\n* Informed Consent: A signed and dated written informed consent prior to study participation.\n* Age: 40 years of age or older at Visit 1.\n* Gender: Male or female subjects.\n* Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society \\[Celli, 2004\\]\n* Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years\n* Severity of Disease: A post-albuterol/salbutamol FEV1/FVC ratio of \\<0.70 and a post-albuterol/salbutamol FEV1 of \\>35% and \\<70% of predicted normal\n* Dyspnea: A score of ≥2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1\n* Resting Lung Volumes: A resting FRC of ≥120% of predicted normal FRC at Visit 1.\n\nExclusion Criteria:\n\n* Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.\n* Asthma: A current diagnosis of asthma.\n* Other Respiratory Disorders: Known respiratory disorders other than COPD including but not limited to alpha-1 antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease. Allergic rhinitis is not exclusionary.\n* Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \\< 5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. Any physical or mental abnormality which would affect the patient carrying out exercise tests including peripheral vascular disease should be excluded at the investigators discretion.\n* Chest X-Ray: A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Visit 1 if a chest X-ray or CT scan is not available within 6 months prior to Visit 1. For subjects in Germany, if a chest X-ray (or CT scan) is not available in the 6 months prior to Visit 1 the subject will not be eligible for the study.\n* Contraindications: A history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.\n* Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.\n* Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).\n* 12-Lead ECG: An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, including the presence of a paced rhythm on a 12-lead electrocardiogram (ECG) which causes the underlying rhythm and ECG to be obscured. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility.\n* Screening Labs: Significantly abnormal finding from clinical chemistry and hematology tests at Visit 1.\n* Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.\n* Medications prior to Screening, including depot,oral corticosteroids, combinations of LABA/ICS, LABA, PDE4 inhibitors.\n* Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., \\<12 hours per day) is not exclusionary.\n* Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy\n* Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.\n* Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.\n* Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period","description":"Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":"13.17"},{"groupId":"OG001","value":"63.2","spread":"23.93"},{"groupId":"OG002","value":"49.8","spread":"23.77"},{"groupId":"OG003","value":"26.7","spread":"19.72"},{"groupId":"OG004","value":"58.6","spread":"13.82"},{"groupId":"OG005","value":"69.1","spread":"13.99"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period","description":"FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.032","spread":"0.0149"},{"groupId":"OG001","value":"0.054","spread":"0.0264"},{"groupId":"OG002","value":"0.108","spread":"0.0263"},{"groupId":"OG003","value":"0.067","spread":"0.0218"},{"groupId":"OG004","value":"0.178","spread":"0.0156"},{"groupId":"OG005","value":"0.136","spread":"0.0158"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period","description":"Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.002","spread":"0.0255"},{"groupId":"OG001","value":"0.025","spread":"0.0457"},{"groupId":"OG002","value":"0.187","spread":"0.0457"},{"groupId":"OG003","value":"0.067","spread":"0.0377"},{"groupId":"OG004","value":"0.196","spread":"0.0269"},{"groupId":"OG005","value":"0.168","spread":"0.0270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.028","spread":"0.0259"},{"groupId":"OG001","value":"0.142","spread":"0.0463"},{"groupId":"OG002","value":"0.249","spread":"0.0462"},{"groupId":"OG003","value":"0.160","spread":"0.0382"},{"groupId":"OG004","value":"0.267","spread":"0.0274"},{"groupId":"OG005","value":"0.250","spread":"0.0275"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period","description":"Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.0494"},{"groupId":"OG001","value":"-0.262","spread":"0.0899"},{"groupId":"OG002","value":"-0.241","spread":"0.0890"},{"groupId":"OG003","value":"-0.109","spread":"0.0738"},{"groupId":"OG004","value":"-0.219","spread":"0.0523"},{"groupId":"OG005","value":"-0.350","spread":"0.0524"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.081","spread":"0.0495"},{"groupId":"OG001","value":"-0.358","spread":"0.0893"},{"groupId":"OG002","value":"-0.456","spread":"0.0885"},{"groupId":"OG003","value":"-0.229","spread":"0.0734"},{"groupId":"OG004","value":"-0.384","spread":"0.0523"},{"groupId":"OG005","value":"-0.548","spread":"0.0526"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period","description":"Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.039","spread":"0.0521"},{"groupId":"OG001","value":"-0.337","spread":"0.0948"},{"groupId":"OG002","value":"-0.249","spread":"0.0940"},{"groupId":"OG003","value":"-0.138","spread":"0.0779"},{"groupId":"OG004","value":"-0.255","spread":"0.0552"},{"groupId":"OG005","value":"-0.432","spread":"0.0553"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.086","spread":"0.0526"},{"groupId":"OG001","value":"-0.375","spread":"0.0955"},{"groupId":"OG002","value":"-0.451","spread":"0.0945"},{"groupId":"OG003","value":"-0.253","spread":"0.0784"},{"groupId":"OG004","value":"-0.437","spread":"0.0556"},{"groupId":"OG005","value":"-0.625","spread":"0.0560"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period","description":"FEVI is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.007","spread":"0.0159"},{"groupId":"OG001","value":"0.122","spread":"0.0277"},{"groupId":"OG002","value":"0.156","spread":"0.0275"},{"groupId":"OG003","value":"0.115","spread":"0.0229"},{"groupId":"OG004","value":"0.254","spread":"0.0166"},{"groupId":"OG005","value":"0.217","spread":"0.0169"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":170},"commonTop":["Nasopharyngitis","Headache","Sinusitis","Dry mouth"]}}}